1PY5

Crystal Structure of TGF-beta receptor I kinase with inhibitor

Summary for 1PY5

• Entry DOI: 10.2210/pdb1py5/pdb
• Related: 1PYE
• Descriptor: TGF-beta receptor type I, SULFATE ION, 4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)QUINOLINE, ... (4 entities in total)
• Functional Keywords: tgf-beta, receptor i, kinase, transferase
• Biological source: Homo sapiens (human)
• Cellular location: Membrane; Single-pass type I membrane protein: P36897
• Total number of polymer chains: 1
• Total formula weight: 37470.96

Authors

Zhang, F.,Sawyer, J.S. (deposition date: 2003-07-08, release date: 2004-07-13, Last modification date: 2023-08-16)

Primary citation

Sawyer, J.S.,Beight, D.W.,Britt, K.S.,Anderson, B.D.,Campbell, R.M.,Goodson, T.,Herron, D.K.,Li, H.Y.,McMillen, W.T.,Mort, N.,Parsons, S.,Smith, E.C.,Wagner, J.R.,Yan, L.,Zhang, F.,Yingling, J.M.
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Bioorg.Med.Chem.Lett., 14:3581-3584, 2004

PubMed Abstract: We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

PubMed: 15177479
DOI: 10.1016/j.bmcl.2004.04.007

Experimental method

X-RAY DIFFRACTION (2.3 Å)